Iridex Corporation announced a recently published independent, retrospective study in Ophthalmology and Therapy, that demonstrates that retreatment of transscleral laser treatment using MicroPulse technology (MicroPulse TLT) can safely and effectively further reduce intraocular pressure (IOP) in patients with glaucoma.

The study, conducted at the University Eye Clinic Maastricht, aimed to assess the effectiveness, repeatability, and safety of retreatment in real-world clinical practice using MicroPulse TLT. The study included 76 eyes from patients with moderate to advanced glaucoma who underwent retreatment following variable responses to their primary procedure. Three months after retreatment, all patient groups demonstrated meaningful IOP reductions, ranging from approximately 25% to 35%, regardless of their prior response to the primary treatment, Iridex Corporation said in a press release.

According to the company, retreatment timing varied widely across patient groups, reflecting the individualized nature of glaucoma management. On average, patients received their first retreatment as early as approximately 4 months in nonresponders and as late as more than 28 months in patients with late-attrition, depending on when the effect of the primary procedure began to diminish.

In addition, among the subset of patients who required a second retreatment, intervals ranged from about 3 months to nearly 2 years in enhancement cases. This variability demonstrates the procedure’s real-world flexibility in sustaining IOP control over time, the company said in the press release.